Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
9
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2023年4月1日〜2023年9月30日ConsolidatedIFRSNet Sales73,314¥ millionYear on year +3.1%Progress 49.9%
Operating profit20,878¥ millionYear on year +9.0%Progress 62.3%
Ordinary income21,146¥ millionYear on year +9.0%Progress 62.2%
Net income attributable to owners of the parent16,176¥ millionYear on year +6.3%Progress 62.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share240.17円
Financial position at period-end
Total assets249,499¥ million
of which net assets 211,774 ¥ millionEquity ratio 84.8%vs. prior year-end +2.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+7,938
Investment-1,693
Financials-4,685
Net change+1,560
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥62,855 million
Segment revenuePharmaceuticals Business ¥60,988 million (YoY +0.8%), Functional Foods Business ¥12,325 million (YoY +15.9%)
Segment profitPharmaceuticals Business ¥18,996 million, Functional Foods Business ¥754 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥147,000 million (YoY +2.0%)
Operating profit¥33,500 million (YoY +11.5%)
Ordinary income¥34,000 million (YoY +11.5%)
Net income¥26,000 million (YoY +14.0%)
Revision to Earnings ForecastNet Sales Not disclosed → ¥147,000 million / Operating profit Not disclosed → ¥33,500 million / Ordinary income Not disclosed → ¥34,000 million / Net income Not disclosed → ¥26,000 million
Annual Dividend Forecast¥114 → ¥124（+8.8%）
Factors Behind Changes in Business Performance
増収と売上構成による売上原価率の低下等。医薬品事業では「ウプトラビ」、海外売上に伴うロイヤリティ収入、「ビルテプソ」等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not disclosed
Depreciation and amortization¥2,462 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and securities analysts)
Issued Shares at Period-End70,251,484 Shares
Treasury Shares at Period-End2,898,706 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年4月1日〜2023年9月30日 |
| Net Sales | ¥73,314 million (YoY +3.1%) |
| Operating profit | ¥20,878 million (YoY +9.0%) |
| Ordinary income | ¥21,146 million (YoY +9.0%) |
| Profit attributable to owners of the parent | ¥16,176 million (YoY +6.3%) |
| Net income per share | 240.17円 |
| Equity ratio | End of the current fiscal period 84.8 / End of previous period 82.4 |
| Total assets | ¥249,499 million |
| Net assets | ¥211,774 million |
| Cash flows from operating activities | ¥7,938 million |
| Cash flows from investing activities | ¥-1,693 million |
| Cash flows from financing activities | ¥-4,685 million |
| Cash and cash equivalents at end of period | ¥62,855 million |
| Full-year earnings forecast | Net Sales ¥147,000 million (YoY +2.0%) / Operating profit ¥33,500 million (YoY +11.5%) / Ordinary income ¥34,000 million (YoY +11.5%) / Net income ¥26,000 million (YoY +14.0%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥147,000 million / Operating profit Not disclosed → ¥33,500 million / Ordinary income Not disclosed → ¥34,000 million / Net income Not disclosed → ¥26,000 million |
| Annual Dividend Forecast | ¥114 → ¥124（+8.8%） |
| Segment revenue | Pharmaceuticals Business ¥60,988 million (YoY +0.8%), Functional Foods Business ¥12,325 million (YoY +15.9%) |
| Segment profit | Pharmaceuticals Business ¥18,996 million, Functional Foods Business ¥754 million |
| Depreciation and amortization | ¥2,462 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 70,251,484 Shares |
| Treasury Shares at Period-End | 2,898,706 Shares |
| Factors Behind Changes in Business Performance | 増収と売上構成による売上原価率の低下等。医薬品事業では「ウプトラビ」、海外売上に伴うロイヤリティ収入、「ビルテプソ」等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加した。 |
Items this document does not state (8)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.増収と売上構成による売上原価率の低下等により営業利益が増加した。医薬品事業では「ウプトラビ」、海外売上に伴うロイヤリティ収入、「ビルテプソ」等が伸長し、機能食品事業ではプロテイン製剤、サプリメント等の売上が増加した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.